美國Dendreon www.dendreon.com
美國Dendreon公司的前列腺癌疫苗

Dendreon Corporation (NASDAQ: DNDN), a Seattle-based biotechnology company, is focused on targeting cancer Cancer
Cancer develops when cells in the body begin to grow out of control. Normal cells grow, divide, and die. Instead of dying, cancer cells continue to grow and form new abnormal cells. Cancer cells often travel to other body parts where they grow and replace normal tissue. This spreading process is called metastasis. When cancer spreads or metastasizes, it is still named after the part of the body where it started. For example, if prostate cancer spreads to the bones, it is still prostate cancer, not bone cancer. Some cancers, such as blood cancers, do not form a tumor. Not all tumors are cancer. A tumor that is not cancer is called benign and does not grow and spread the way cancer does.Closeto transform lives through the discovery, development and commercialization of novel therapeutics to fight cancer.
Dendreon applies its expertise in antigen Antigen
A substance that causes the body's immune system to react. This reaction often involves production of antibodies. For example, the immune system's response to antigens that are part of bacteria and viruses helps people resist infections. Cancer cells have certain antigens that can be found by laboratory tests. They are important in cancer diagnosis and in watching response to treatment. Other cancer cell antigens play a role in immune reactions that may help the body's resistance against cancer. Closeidentification, engineering and cell processing to produce Active Cellular Immunotherapy (ACI) product candidates designed to stimulate an immune response. ACI holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. In addition to ACI product candidates, the company is also developing an orally-available small molecule targeting TRPM8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia.
Dendreon's lead ACI product candidate, known as PROVENGE® (sipuleucel-T) Sipuleucel-T
An investigational product that may represent the first in a new class of active cellular immunotherapies (ACIs).Close, is in late-stage development for the treatment of men with metastatic, androgen-independent Androgen-Independent
Term for prostate cancer cells that no longer respond to hormone therapy; also known as hormone-refractory. Closeprostate Prostate
A gland in the male reproductive system. The prostate surrounds the part of the urethra (the tube that empties the bladder) just below the bladder, and produces a fluid that forms part of the semen.Closecancer.